Research programme: human monoclonal antibodies - Medarex/Protein Design Labs
Alternative Names: Human monoclonal antibodies research programme - Medarex/Protein Design LabsLatest Information Update: 03 May 2007
Price :
$50 *
At a glance
- Originator Medarex; PDL BioPharma
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 May 2007 No development reported - Preclinical for Cancer in USA (unspecified route)
- 29 Jun 2005 This programme is still in active development
- 16 Apr 2003 Eos Biotechnology has been acquired by, and merged into, Protein Design Labs